drugset / Trial / NCT04179396

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

NCT04179396

Phase 1 Completed 8 enrolled pharmaand GmbH
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer

Timeline

Start
2019-12-05
Primary completion
2021-11-25
Completion
2023-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule Oral
Subject Enzalutamide Other / unclassified Oral
Subject Rucaparib Small molecule Oral